Karyopharm Therapeutics (NASDAQ:KPTI) Price Target Raised to $56.00

Karyopharm Therapeutics (NASDAQ:KPTI) had its price target upped by HC Wainwright from $7.00 to $56.00 in a research report report published on Wednesday,Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Karyopharm Therapeutics’ Q1 2025 earnings at ($0.29) EPS, Q3 2025 earnings at ($0.25) EPS, Q4 2025 earnings at ($0.28) EPS, FY2025 earnings at ($1.10) EPS, FY2026 earnings at ($0.87) EPS and FY2027 earnings at ($0.46) EPS.

A number of other analysts have also weighed in on KPTI. StockNews.com lowered shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 22nd. Piper Sandler raised their price target on shares of Karyopharm Therapeutics from $60.00 to $75.00 and gave the company an “overweight” rating in a report on Wednesday, November 6th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $45.00 target price on shares of Karyopharm Therapeutics in a report on Thursday, February 20th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, Karyopharm Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $62.75.

Karyopharm Therapeutics Price Performance

Shares of Karyopharm Therapeutics stock opened at $7.95 on Wednesday. The firm has a market cap of $66.94 million, a P/E ratio of -7.79 and a beta of 0.06. The firm has a 50 day simple moving average of $9.85 and a 200 day simple moving average of $11.28. Karyopharm Therapeutics has a fifty-two week low of $7.61 and a fifty-two week high of $25.50.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings results on Wednesday, February 19th. The company reported ($3.60) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.90) by $0.30. The company had revenue of $30.54 million during the quarter, compared to analyst estimates of $30.29 million. On average, sell-side analysts expect that Karyopharm Therapeutics will post -0.71 EPS for the current year.

Hedge Funds Weigh In On Karyopharm Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in KPTI. Adage Capital Partners GP L.L.C. boosted its position in shares of Karyopharm Therapeutics by 46.3% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 6,319,842 shares of the company’s stock worth $4,274,000 after purchasing an additional 2,000,000 shares in the last quarter. GSA Capital Partners LLP boosted its position in shares of Karyopharm Therapeutics by 80.6% during the third quarter. GSA Capital Partners LLP now owns 1,775,700 shares of the company’s stock worth $1,474,000 after purchasing an additional 792,283 shares in the last quarter. Jane Street Group LLC lifted its position in Karyopharm Therapeutics by 265.5% in the 4th quarter. Jane Street Group LLC now owns 748,306 shares of the company’s stock valued at $506,000 after acquiring an additional 543,556 shares in the last quarter. Marshall Wace LLP lifted its position in Karyopharm Therapeutics by 15.3% in the 4th quarter. Marshall Wace LLP now owns 2,401,413 shares of the company’s stock valued at $1,633,000 after acquiring an additional 319,187 shares in the last quarter. Finally, Shay Capital LLC bought a new stake in Karyopharm Therapeutics in the 4th quarter valued at $116,000. 66.44% of the stock is owned by institutional investors.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).